Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Allogene Therapeutics Inc.
Sponsor

Allogene Therapeutics Inc.

United States 210 Grand Avenue, 94080-3707, United States

About the sponsor

Allogene Therapeutics Inc. focuses its clinical research on large B-cell lymphoma, with studies centered on relapsed/refractory disease and the treatment needs of adults with aggressive blood cancers.

  • Large B-cell lymphoma
  • Relapsed/refractory lymphoma
  • Blood cancer treatment

The sponsor’s clinical activity is concentrated in oncology settings where treatment resistance and disease control are major concerns.

About Specializations

Allogene Therapeutics Inc. runs clinical trials in conditions such as Diffuse large B-cell lymphoma refractory, Diffuse large B-cell lymphoma recurrent, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

2 clinical trials

Diffuse large B-cell lymphoma refractory+1

Not recruiting

Study on the Safety and Effectiveness of ALLO-501A and ALLO-647 for Adults with Relapsed or Refractory Large B-Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Allogene Therapeutics Inc.

Diffuse large B-cell lymphoma refractory+1

Not recruiting

Study on ALLO-647 and ALLO-501A for Adults with Relapsed or Refractory Large B-Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Allogene Therapeutics Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.